Drug intelligence / Profile preview

Actimax

Development stage: Unknown
Lead developer: Max Life Sciences
Modality: Small Molecules
Administration: Oral

Overview

**Actimax** is an oral fixed-dose analgesic and anti-inflammatory tablet marketed by Max Life Sciences containing aceclofenac 100 mg and paracetamol 325 mg. Aceclofenac is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-mediated prostaglandin production, while paracetamol provides primarily central analgesic and antipyretic activity. The product is marketed for relief of pain, inflammation, and fever, including painful musculoskeletal and joint conditions. ([maxlifesciences.in](https://maxlifesciences.in/product/actimax-tablets/))

Brand names: Actimax
Other names: aceclofenac + paracetamol

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Actimax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actimax.

Explore the full profile